Moody's: Baxter's Acquisition of Oncaspar is Credit Negative

New York, May 12, 2015 -- Baxter International's planned acquisition of the Oncaspar oncology product portfolio of Sigma-Tau Finanziaria S.p.A. is credit negative based on Moody's expectation that it will be at least partially debt-funded, and because of the high sales multiple being paid, i.e. 9 times sales. Baxter's A3/Prime-2 ratings remain on review for downgrade pending more information regarding the company's capital structure and financial policies after the upcoming spin-off of its bioscience unit, which will be named Baxalta Inc. For additional information, please refer to Moody's Issuer Comment on Baxter on www.moodys.com.

Vollständigen Artikel bei Moodys lesen